Financials data is unavailable for this security.
View more
Year on year Remus Pharmaceuticals Ltd grew revenues 371.94% from 450.27m to 2.12bn while net income improved 153.29% from 85.03m to 215.37m.
| Gross margin | 22.67% |
|---|---|
| Net profit margin | 12.22% |
| Operating margin | 12.67% |
| Return on assets | 17.80% |
|---|---|
| Return on equity | 40.64% |
| Return on investment | 44.48% |
More ▼
Cash flow in INRView more
In 2024, Remus Pharmaceuticals Ltd increased its cash reserves by 242.62%, or 190.26m. Cash Flow from Financing totalled 243.66m or 11.47% of revenues. In addition the company generated 36.02m in cash from operations while cash used for investing totalled 89.43m.
| Cash flow per share | 47.41 |
|---|---|
| Price/Cash flow per share | 53.17 |
| Book value per share | 147.42 |
|---|---|
| Tangible book value per share | 131.52 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.40 |
|---|---|
| Quick ratio | 1.12 |
| Total debt/total equity | 0.133 |
|---|---|
| Total debt/total capital | 0.0997 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 200.00% and 82.59%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 4.10% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
More ▼
